Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

Meinolf Karthaus, Xaver Schiel, Christina H. Ruhlmann, Luigi Celio

Research output: Contribution to journalReview article

Abstract

Introduction: The addition of neurokinin-1 receptor antagonists (NK1RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. Areas covered: This review presents the evidence base for the use of oral and intravenous (IV) NK1RAs, focusing on the pharmacologic and clinical properties as a class, and highlighting differences between agents. A PubMed literature search was conducted from 2000 to 2018. Expert opinion: Adherence to international antiemetic guidelines remains a clinical challenge. Strategies to simplify antiemetic regimens and facilitate their administration may improve compliance and treatment outcomes. The use of fixed-combination antiemetics offers clinical utility, in combining an NK1RA with a 5-HT3RA in a single oral dose. The use of long-lasting NK1RAs and administering CINV prophylaxis closer to the time of chemotherapy may also assist with guideline and treatment compliance, diminishing the need for home-based administration, and potentially reducing resource utilization. The availability of IV and oral formulations of NK1RAs and NK1RA–5-HT3RA fixed combinations offers further utility, particularly for those patients unsuited for oral administration. However, safety considerations with respect to injection site toxicity and hypersensitivity reactions of the new NK1RA IV formulations deserve close attention.

Original languageEnglish
Pages (from-to)661-680
Number of pages20
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 3 2019

Fingerprint

Neurokinin-1 Receptor Antagonists
Nausea
Vomiting
Drug Therapy
Antiemetics
Serotonin
Guidelines
Expert Testimony
PubMed
Dexamethasone
Compliance
Oral Administration
Hypersensitivity
Safety
Injections

Keywords

  • adherence
  • antiemetics
  • Chemotherapy-induced nausea and vomiting (CINV)
  • emesis
  • guidelines

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Neurokinin-1 receptor antagonists : review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. / Karthaus, Meinolf; Schiel, Xaver; Ruhlmann, Christina H.; Celio, Luigi.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 7, 03.07.2019, p. 661-680.

Research output: Contribution to journalReview article

@article{c97110a5f3834b1f962ccd579b6354b4,
title = "Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults",
abstract = "Introduction: The addition of neurokinin-1 receptor antagonists (NK1RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. Areas covered: This review presents the evidence base for the use of oral and intravenous (IV) NK1RAs, focusing on the pharmacologic and clinical properties as a class, and highlighting differences between agents. A PubMed literature search was conducted from 2000 to 2018. Expert opinion: Adherence to international antiemetic guidelines remains a clinical challenge. Strategies to simplify antiemetic regimens and facilitate their administration may improve compliance and treatment outcomes. The use of fixed-combination antiemetics offers clinical utility, in combining an NK1RA with a 5-HT3RA in a single oral dose. The use of long-lasting NK1RAs and administering CINV prophylaxis closer to the time of chemotherapy may also assist with guideline and treatment compliance, diminishing the need for home-based administration, and potentially reducing resource utilization. The availability of IV and oral formulations of NK1RAs and NK1RA–5-HT3RA fixed combinations offers further utility, particularly for those patients unsuited for oral administration. However, safety considerations with respect to injection site toxicity and hypersensitivity reactions of the new NK1RA IV formulations deserve close attention.",
keywords = "adherence, antiemetics, Chemotherapy-induced nausea and vomiting (CINV), emesis, guidelines",
author = "Meinolf Karthaus and Xaver Schiel and Ruhlmann, {Christina H.} and Luigi Celio",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/17512433.2019.1621162",
language = "English",
volume = "12",
pages = "661--680",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "7",

}

TY - JOUR

T1 - Neurokinin-1 receptor antagonists

T2 - review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

AU - Karthaus, Meinolf

AU - Schiel, Xaver

AU - Ruhlmann, Christina H.

AU - Celio, Luigi

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Introduction: The addition of neurokinin-1 receptor antagonists (NK1RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. Areas covered: This review presents the evidence base for the use of oral and intravenous (IV) NK1RAs, focusing on the pharmacologic and clinical properties as a class, and highlighting differences between agents. A PubMed literature search was conducted from 2000 to 2018. Expert opinion: Adherence to international antiemetic guidelines remains a clinical challenge. Strategies to simplify antiemetic regimens and facilitate their administration may improve compliance and treatment outcomes. The use of fixed-combination antiemetics offers clinical utility, in combining an NK1RA with a 5-HT3RA in a single oral dose. The use of long-lasting NK1RAs and administering CINV prophylaxis closer to the time of chemotherapy may also assist with guideline and treatment compliance, diminishing the need for home-based administration, and potentially reducing resource utilization. The availability of IV and oral formulations of NK1RAs and NK1RA–5-HT3RA fixed combinations offers further utility, particularly for those patients unsuited for oral administration. However, safety considerations with respect to injection site toxicity and hypersensitivity reactions of the new NK1RA IV formulations deserve close attention.

AB - Introduction: The addition of neurokinin-1 receptor antagonists (NK1RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. Areas covered: This review presents the evidence base for the use of oral and intravenous (IV) NK1RAs, focusing on the pharmacologic and clinical properties as a class, and highlighting differences between agents. A PubMed literature search was conducted from 2000 to 2018. Expert opinion: Adherence to international antiemetic guidelines remains a clinical challenge. Strategies to simplify antiemetic regimens and facilitate their administration may improve compliance and treatment outcomes. The use of fixed-combination antiemetics offers clinical utility, in combining an NK1RA with a 5-HT3RA in a single oral dose. The use of long-lasting NK1RAs and administering CINV prophylaxis closer to the time of chemotherapy may also assist with guideline and treatment compliance, diminishing the need for home-based administration, and potentially reducing resource utilization. The availability of IV and oral formulations of NK1RAs and NK1RA–5-HT3RA fixed combinations offers further utility, particularly for those patients unsuited for oral administration. However, safety considerations with respect to injection site toxicity and hypersensitivity reactions of the new NK1RA IV formulations deserve close attention.

KW - adherence

KW - antiemetics

KW - Chemotherapy-induced nausea and vomiting (CINV)

KW - emesis

KW - guidelines

UR - http://www.scopus.com/inward/record.url?scp=85067843867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067843867&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1621162

DO - 10.1080/17512433.2019.1621162

M3 - Review article

C2 - 31194593

AN - SCOPUS:85067843867

VL - 12

SP - 661

EP - 680

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 7

ER -